Compare RAIL & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | RCEL |
|---|---|---|
| Founded | 1901 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Railroads | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.9M | 126.8M |
| IPO Year | 2005 | N/A |
| Metric | RAIL | RCEL |
|---|---|---|
| Price | $7.98 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 349.0K | ★ 358.4K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $500,991,000.00 | N/A |
| Revenue This Year | $6.54 | $17.17 |
| Revenue Next Year | $30.90 | $49.82 |
| P/E Ratio | $7.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.27 | $3.22 |
| 52 Week High | $14.90 | $7.12 |
| Indicator | RAIL | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 44.64 |
| Support Level | $7.58 | $3.92 |
| Resistance Level | $8.12 | $4.56 |
| Average True Range (ATR) | 0.54 | 0.35 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 10.27 | 24.42 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.